Patents by Inventor Mohamed S. A. Elsayed
Mohamed S. A. Elsayed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124453Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: ApplicationFiled: November 17, 2023Publication date: April 18, 2024Applicant: Array BioPharma Inc.Inventors: James Francis BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam Wade COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John P. FISCHER, Ronald Jay HINKLIN, Yutong JIANG, Oren Teague MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina Elizabeth WONG
-
Patent number: 11884664Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: April 13, 2022Date of Patent: January 30, 2024Assignee: Array BioPharma Inc.Inventors: James Francis Blake, Mark Laurence Boys, Mark Joseph Chicarelli, Adam Wade Cook, Mohamed S. A. Elsayed, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Yutong Jiang, Oren Teague McNulty, Macedonio J. Mejia, Martha E. Rodriguez, Christina Elizabeth Wong
-
Patent number: 11787787Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.Type: GrantFiled: February 2, 2021Date of Patent: October 17, 2023Assignee: Purdue Research FoundationInventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S. A. Elsayed
-
Patent number: 11634417Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: March 31, 2020Date of Patent: April 25, 2023Assignee: Array BioPharma Inc.Inventors: James F. Blake, Mark Laurence Boys, Mark Joseph Chicarelli, Adam W. Cook, Mohamed S. A. Elsayed, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Yutong Jiang, Oren T. McNulty, Macedonio J. Mejia, Martha E. Rodriguez, Christina E. Wong
-
Publication number: 20220251083Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: ApplicationFiled: April 13, 2022Publication date: August 11, 2022Applicant: Array BioPharma Inc.Inventors: James Francis BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam Wade COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John P. FISCHER, Ronald Jay HINKLIN, Yutong JIANG, Oren Teague MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina Elizabeth WONG
-
Publication number: 20210380582Abstract: Compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases.Type: ApplicationFiled: October 17, 2019Publication date: December 9, 2021Applicant: Array BioPharma Inc.Inventors: James Francis BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam Wade COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John Peter FISCHER, Ronald Jay HINKLIN, Oren Teague MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina Elizabeth WONG
-
Publication number: 20210155614Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.Type: ApplicationFiled: February 2, 2021Publication date: May 27, 2021Applicant: Purdue Research FoundationInventors: Richard M. Van Rijn, Mark S. Cushman, Markus Lill, Robert J. Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S.A. Elsayed
-
Patent number: 10954224Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.Type: GrantFiled: June 8, 2018Date of Patent: March 23, 2021Assignee: Purdue Research FoundationInventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S. A. Elsayed
-
Patent number: 10875860Abstract: Tyrosyl-DNA Phosphodiesterases 1 and 2 (Tdp1 and Tdp2) can repair damaged DNA resulting from topoisomerase inhibitors (e.g. Top1) and a variety of other DNA-damaging agents. 7-Azaindenoisoquinolines that are inhibitors of each of Top1, Tdp1 and Tdp2 are disclosed. Also described are methods for preparing azaindenoisoquinoline and methods for treating patients of a cancer using the disclosed azaindenoisoquinoline compounds or a pharmaceutical formulation thereof.Type: GrantFiled: December 19, 2017Date of Patent: December 29, 2020Assignees: PURDUE RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Mark S. Cushman, Ping Wang, Yves George Pommier, Mohamed S. A. Elsayed
-
Publication number: 20200317665Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: ApplicationFiled: March 31, 2020Publication date: October 8, 2020Applicant: Array BioPharma Inc.Inventors: James F. BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam W. COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John P. FISCHER, Ronald Jay HINKLIN, Yutong JIANG, Oren T. MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina E. WONG
-
Publication number: 20200199111Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.Type: ApplicationFiled: June 8, 2018Publication date: June 25, 2020Applicant: Purdue Research FoundationInventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S.A. Elsayed
-
Publication number: 20200095243Abstract: Tyrosyl-DNA Phosphodiesterases 1 and 2 (Tdp1 and Tdp2) can repair damaged DNA resulting from topoisomerase inhibitors (e.g. Top1) and a variety of other DNA-damaging agents. 7-Azaindenoisoquinolines that are inhibitors of each of Top1, Tdp1 and Tdp2 are disclosed. Also described are methods for preparing azaindenoisoquinoline and methods for treating patients of a cancer using the disclosed azaindenoisoquinoline compounds or a pharmaceutical formulation thereof.Type: ApplicationFiled: December 19, 2017Publication date: March 26, 2020Inventors: Mark S. Cushman, Ping Wang, Yves George Pommier, Mohamed S.A. Elsayed
-
Patent number: 10399979Abstract: The invention described herein pertains to selective Janus kinase (JAK) inhibitors and methods of use thereof. Also described are methods for treating diseases involved abnormal JAK/STAT signaling pathway in mammals using the described selective JAK inhibitors or a pharmaceutical formulation thereof.Type: GrantFiled: October 31, 2018Date of Patent: September 3, 2019Assignee: Purdue Research FoundationInventors: Mark Stanley Cushman, Mohamed S. A. Elsayed
-
Publication number: 20190127377Abstract: The invention described herein pertains to selective Janus kinase (JAK) inhibitors and methods of use thereof. Also described are methods for treating diseases involved abnormal JAK/STAT signaling pathway in mammals using the described selective JAK inhibitors or a pharmaceutical formulation thereof.Type: ApplicationFiled: October 31, 2018Publication date: May 2, 2019Applicant: Purdue Research FoundationInventors: Mark Stanley Cushman, Mohamed S. A. Elsayed